<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2009-15-5-559-564</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-1433</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Сравнительная оценка антигипертензивного и кардиогемодинамических эффектов комбинаций диуретика с различными производными антагонистов кальция у больных артериальной гипертензией</article-title><trans-title-group xml:lang="en"><trans-title>Combination therapy with diuretic and different calcium antagonists in hypertensive patients: The comparison of antihypertensive and hemodynamic effects</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Искендеров</surname><given-names>Б. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Iskenderov</surname><given-names>B. G.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гриднева</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gridneva</surname><given-names>E. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сисина</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Sisina</surname><given-names>O. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саушкина</surname><given-names>СВ. ..</given-names></name><name name-style="western" xml:lang="en"><surname>Saushkina</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГОУ ДПО «Пензенский институт усовершенствования врачей Федерального агентства по здравоохранению и социальному развитию»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Penza Advanced Training Institute for Doctors, Penza, Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>28</day><month>10</month><year>2009</year></pub-date><volume>15</volume><issue>5</issue><fpage>559</fpage><lpage>564</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Искендеров Б.Г., Гриднева Е.В., Сисина О.Н., Саушкина С..., 2009</copyright-statement><copyright-year>2009</copyright-year><copyright-holder xml:lang="ru">Искендеров Б.Г., Гриднева Е.В., Сисина О.Н., Саушкина С...</copyright-holder><copyright-holder xml:lang="en">Iskenderov B.G., Gridneva E.V., Sisina O.N., Saushkina S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/1433">https://htn.almazovcentre.ru/jour/article/view/1433</self-uri><abstract><p>Обследовано 59 больных артериальной гипертензией 2-й степени в возрасте 48-65 лет. В исходном состоянии и через 16 недель после лечения проводились суточное мониторирование артериального давления (АД) и допплер-эхокардиография. Больные были рандомизированы на 2 группы. Больные 1-й группы получали комбинированную терапию индапамидом и верапамилом ретард, пациенты 2-й группы - индапамидом и амлодипином. Циркадный ритм АД в 1-й группе нормализовался у 83,9 % больных и во 2-й группе - у 78,6 %. Показано, что в 1-й группе комбинированная терапия наиболее эффективна у больных с диастолической дисфункцией левого желудочка (ДДЛЖ) I типа, суточным профилем «нон-диппер» и гиперкинетическим типом кровообращения. Во 2-й группе выраженные сдвиги показателей наблюдались при II-III типе ДДЛЖ и гипокинетическом типе кровообращения.</p></abstract><trans-abstract xml:lang="en"><p>54 patients 42-65 years old with uncomplicated hypertension (stage 2) were studied. The 24-hour blood pressure (ВР) monitoring and doppler-echocardiograpy were performed at baseline and after 16 weeks of treatment. Patients were randomized into 2 groups. In the 1st group patients received combination indapamide with verapamil retard, and in 2nd group, combination of indapamide with amlodipine. The circadian rhythm of BP profile was normalized in 83,9 % of patients in 1st group and in 78,6 % of patients in the 2nd group. In the 1st group, the combination therapy is more effective in patients with diastolic left ventricular dysfunction (DDLV) type I, non-dipper profile of circadian rhythm of BP, and with a hyperkinetic type of circulation. In the 2nd group, combination therapy was effective in patients with DDLV type 2-3 and with a hypokinetic type of circulation.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>комбинированная терапия</kwd><kwd>индапамид</kwd><kwd>верапамил ретард</kwd><kwd>амлодипин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypertension</kwd><kwd>combined therapy</kwd><kwd>indapamide</kwd><kwd>verapamil retard</kwd><kwd>amlodipine</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (третий пересмотр) // Кардиоваск. терапия и профилактика. 2008. - № 6 (Прил. 2). - С. 3-32.</mixed-citation><mixed-citation xml:lang="en">Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов (третий пересмотр) // Кардиоваск. терапия и профилактика. 2008. - № 6 (Прил. 2). - С. 3-32.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Матова И.Е., Воинов С.Л., Остроумова О.Д. Комбинированная терапия больных артериальной гипертонией // Методическое письмо. - М. : «Атмосфера», 2004. - 48 с.</mixed-citation><mixed-citation xml:lang="en">Матова И.Е., Воинов С.Л., Остроумова О.Д. Комбинированная терапия больных артериальной гипертонией // Методическое письмо. - М. : «Атмосфера», 2004. - 48 с.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lefrandi J.D., Heitmann J., Sevre S. et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study //Am. J. Hypertens. 2001. - Vol. 14, № II, Pt. 1. - P. 1083-1089.</mixed-citation><mixed-citation xml:lang="en">Lefrandi J.D., Heitmann J., Sevre S. et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study //Am. J. Hypertens. 2001. - Vol. 14, № II, Pt. 1. - P. 1083-1089.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (EHS) and the European Society of Cardiology (ESC) // Eur. Heart J. - 2007. - Vol. 28. - P. 1462-1536.</mixed-citation><mixed-citation xml:lang="en">Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (EHS) and the European Society of Cardiology (ESC) // Eur. Heart J. - 2007. - Vol. 28. - P. 1462-1536.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Staessen J., Ji-Guang Wang, Thijs L. Calcium channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trail //Am. J. Hypertens. - 2002. - Vol. 15, № 7, Pt. 2. - P. 85S-93S.</mixed-citation><mixed-citation xml:lang="en">Staessen J., Ji-Guang Wang, Thijs L. Calcium channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trail //Am. J. Hypertens. - 2002. - Vol. 15, № 7, Pt. 2. - P. 85S-93S.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Devereux R., Reichek N. Echocardiography assessment of left ventricular mass in man. Anatomic validation of the method // Circulation. - 1977. - Vol. 55, № 4. - P. 613-618.</mixed-citation><mixed-citation xml:lang="en">Devereux R., Reichek N. Echocardiography assessment of left ventricular mass in man. Anatomic validation of the method // Circulation. - 1977. - Vol. 55, № 4. - P. 613-618.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Abernethy D.R., Schwartz J.B. Calcium-antagonists drugs //N. Engl. J. Med. - 1999. - Vol. 341, № 19. - P. 1447-1457.</mixed-citation><mixed-citation xml:lang="en">Abernethy D.R., Schwartz J.B. Calcium-antagonists drugs //N. Engl. J. Med. - 1999. - Vol. 341, № 19. - P. 1447-1457.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С.Ю. Антагонисты кальция: выбор терапии при артериальной гипертонии // Артериальная гипертония. - 2004. - № 4. - С. 193-198.</mixed-citation><mixed-citation xml:lang="en">Марцевич С.Ю. Антагонисты кальция: выбор терапии при артериальной гипертонии // Артериальная гипертония. - 2004. - № 4. - С. 193-198.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Opie L., Schall R. Evidence-based evaluations of calcium channel blockers for hypertension // J. Am. Coll. Cardiol. 2002. - Vol. 39, №2. - P. 315-322.</mixed-citation><mixed-citation xml:lang="en">Opie L., Schall R. Evidence-based evaluations of calcium channel blockers for hypertension // J. Am. Coll. Cardiol. 2002. - Vol. 39, №2. - P. 315-322.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker versus diuretic (ALLHAT) // J. Am. Med. Ass. - 2002. - Vol. 288, №23. - P. 2981-2997.</mixed-citation><mixed-citation xml:lang="en">The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker versus diuretic (ALLHAT) // J. Am. Med. Ass. - 2002. - Vol. 288, №23. - P. 2981-2997.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Noll G., Luscher T.F. Comparative pharmacological properties among calcium channel blockers; T-channel versus L-channel blockade // Cardiology. - 1998. - Vol. 89 (Suppl. 1). - P. 10-15.</mixed-citation><mixed-citation xml:lang="en">Noll G., Luscher T.F. Comparative pharmacological properties among calcium channel blockers; T-channel versus L-channel blockade // Cardiology. - 1998. - Vol. 89 (Suppl. 1). - P. 10-15.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Кушаковский M.C. Гипертоническая болезнь (эссенциальная гипертония): причины, механизмы, клиника, лечение. - СПб. : СО-ТИС, 1995. - 320 с.</mixed-citation><mixed-citation xml:lang="en">Кушаковский M.C. Гипертоническая болезнь (эссенциальная гипертония): причины, механизмы, клиника, лечение. - СПб. : СО-ТИС, 1995. - 320 с.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) // Lancet. - 2000. - Vol. 356, № 9227. - P. 366-372.</mixed-citation><mixed-citation xml:lang="en">Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) // Lancet. - 2000. - Vol. 356, № 9227. - P. 366-372.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Eisenberg M.J., Brox A., Bcstawros A.N. Calcium channel blockers // Am. J. Med. 2004. - Vol. 116, № 1. - P. 35-43.</mixed-citation><mixed-citation xml:lang="en">Eisenberg M.J., Brox A., Bcstawros A.N. Calcium channel blockers // Am. J. Med. 2004. - Vol. 116, № 1. - P. 35-43.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Недогода С.В. Диуретики при артериальной гипертензии. - М.: ООО «МАИ», 2008. - 175 с.</mixed-citation><mixed-citation xml:lang="en">Недогода С.В. Диуретики при артериальной гипертензии. - М.: ООО «МАИ», 2008. - 175 с.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Black H.R., Elliott W.J., Grandits G. et al. Principal result of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial // J. Am. Med. Ass. - 2003. - Vol. 28, № 16. - P. 2073 2082.</mixed-citation><mixed-citation xml:lang="en">Black H.R., Elliott W.J., Grandits G. et al. Principal result of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial // J. Am. Med. Ass. - 2003. - Vol. 28, № 16. - P. 2073 2082.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
